Further to Decision 46 COM 9A, this document presents a report on the implementation of the Upstream Process requests since the 46th session of the World Heritage Committee (New Delhi, 2024). It also ...

Process intensification has reduced the cost of mAb manufacturing, but tweaks across bioproduction will be needed to reduce ...

Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

Bioprocessing comprises the integrated design, optimisation and control of biological systems used to produce commercially valuable products. It harnesses living cells, enzymes or whole organisms, ...

Polyethylenimine (PEI)-assisted transfection is a mainstay in upstream processing (USP) for viral vector manufacturing. But recent developments are shifting it from a ...